CBD-ESPRIT
ID: 5b9b4d407db23a2b77818be1
3 Documents
Close
3 References ( articles) loading Revert Studify

Primary study

Unclassified

Enhancing recovery in early schizophrenia–a controlled clinical trial investigating cannabidiol Cr vs. placebo as an add-on to antipsychotic treatment

blocked
Conference 9th International Conference on Early Psychosis (Published in: Early Intervention in Psychiatry)
Year 2014

This article is not included in any systematic review

Loading references information
Current antipsychotic treatments of schizophrenia are only partially effective, and their use is often associated with serious side effects. Cannabidiol is a natural counterpart of the psychoactive component of marijuana, delta-9-tetrahydrocannabinol and has no psychotomimetic or addictive properties. In a controlled clinical trial of cannabidiol versus amisulpride in acute paranoid schizophrenia we showed a statistically signifi cant clinical improvement in all symptoms clusters of schizophrenia compared to baseline with either treatment. Cannabidiol displayed a signifi cantly superior side-effect profi le in particular regarding prolactin elevation, extrapyramidal symptoms and weight gain. The favorable side-effect profi le and potentially novel mechanism of action identify this molecule as a potential antipsychotic. However, long-term safety and effi cacy data is still lacking. This study in 180 remitted schizophrenia patients is to evaluate the effi - cacy and safety of the novel compound cannabidiol in the maintenance treatment of schizophrenia in comparison to placebo as an add-on to an established treatment with either olanzapine or amisulpride, in a 12 months, double-blind, parallel-group, randomized, placebo-controlled clinical trial. Thereby, relevant data on cannabidiol ’ s antipsychotic potential will be gained.

Primary study

Unclassified

Enhancing Recovery in Early Schizophrenia

blocked
Registry of Trials clinicaltrials.gov
Year 2017
Links Registry of Trials

This article is not included in any systematic review

Loading references information
Current antipsychotic treatments of schizophrenia are only partially effective, and their use is often associated with serious side effects. Cannabidiol is a natural counterpart of the psychoactive component of marijuana, delta-9- tetrahydrocannabinol and has no psychotomimetic or addictive properties. In a controlled clinical trial of cannabidiol versus amisulpride in acute paranoid schizophrenia we showed a statistically significant clinical improvement in all symptoms clusters of schizophrenia compared to baseline with either treatment. Cannabidiol displayed a significantly superior side-effect profile in particular regarding prolactin elevation, extrapyramidal symptoms and weight gain. The favorable side-effect profile and potentially novel mechanism of action identify this molecule as a potential antipsychotic. However, long-term safety and efficacy data is still lacking. This study is to evaluate the efficacy and safety of the novel compound cannabidiol in the maintenance treatment of schizophrenia in comparison to placebo as an add-on to an established treatment with either amisulpride, aripiprazole, olanzapine, quetiapine or risperidone, in a 12-months, double-blind, parallel-group, randomized, placebo-controlled clinical trial. Thereby, relevant data on cannabidiol\'s antipsychotic potential will be gained.

Primary study

Unclassified

Enhancing recovery in early schizophrenia by randomized controlled add-on of cannabidiol to an individualized antipsychotic treatment

blocked
Journal Enhancing recovery in early schizophrenia by randomized controlled add-on of cannabidiol to an individualized antipsychotic treatment
Year 2018
Links DOI

This article is not included in any systematic review

Loading references information
Despite recent advances, the treatment of schizophrenic psychoses remains a considerable challenge when remission is the goal. Although acute psychotic symptoms respond quite well to current antipsychotics, their limited effects on negative symptoms and cognitive decline as well as their side-effect profile are still problematic regarding full recovery of social and vocational performance and integration for a substantial number of patients. The ESPRIT research network is focussed on early stages of psychosis and will examine the therapeutic potential of cannabidol as an add-on treatment in post-acute schizophrenia. In this double blind randomized clinical trial, longer-term efficacy and safety of the compound will be investigated. Cannabidiol acts by modulating the function of the endocannabinoid system. Thereby, it represents a potentially new class of antipsychotic compounds, hopefully effective to improve recovery of schizophrenic patients.